Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Trading 09-08 12:37:33 EDT

102.13

-0.61

-0.60%

High103.31	Low99.41	Vol186.49K
Open100.58	D1 Closing102.74	Amplitude3.80%
Mkt Cap7.03B	Tradable Cap6.68B	Total Shares68.85M
T/O19.01M	T/O Rate0.29%	Tradable Shares65.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":102.125,"timestamp":1788885445095,"preClose":102.74,"halted":0,"volume":186486,"delay":0,"changeRate":-0.00598598403737585,"floatShares":65394076,"shares":68852082,"eps":-3.117162,"marketStatus":"Trading","change":-0.615,"latestTime":"09-08 12:37:33 EDT","open":100.58,"high":103.31,"low":99.41,"amount":19008529.16916,"amplitude":0.03796,"askPrice":102.25,"askSize":94,"bidPrice":101.79,"bidSize":210,"shortable":3,"etf":0,"ttmEps":-3.117162,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788897600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":102.74,"preHourTrading":{"tag":"盘前","latestPrice":100.88,"preClose":102.74,"latestTime":"09:29 EDT","volume":807,"amount":81730.38567,"timestamp":1788874194154,"change":-1.86,"changeRate":-0.018104,"amplitude":0.081662},"postHourTrading":{"tag":"盘后","latestPrice":102.74,"preClose":102.74,"latestTime":"19:30 EDT","volume":8796,"amount":903701.04,"timestamp":1788564604191,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.841178,"impliedVol":0.3946,"impliedVolPercentile":0.0199},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2664693738","title":"Rhythm Pharma CFO Hunter C. Smith Disposes of Common Shares Worth $6.61 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664693738","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664693738?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:23","pubTimestamp":1788294223,"startTime":"0","endTime":"0","summary":"Rhythm Pharma CFO Hunter C. Smith disposes of common shares worth $6.61 millionRhythm Pharmaceuticals CFO Hunter C. Smith exercised employee stock options for 57,187 shares at USD 25.79 on Aug. 31, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL99QwGr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharma CFO Hunter C. Smith Disposes of Common Shares Worth $6.61 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4588","MEDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663021276","title":"Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ (RYTM) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2663021276","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663021276?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:16","pubTimestamp":1788139015,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals has received marketing authorization in Japan for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, the first approved therapy in that indication, supported by positive Phase 3 TRANSCEND data showing a statistically significant placebo-adjusted reduction in body mass index.\nThis approval opens a new rare-disease market in Japan, where Rhythm estimates 5,000 to 8,000 people live with acquired hypothalamic obesity, potentially expanding the company’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/will-japans-first-imcivree-approval-in-hypothalamic-obesity","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/will-japans-first-imcivree-approval-in-hypothalamic-obesity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","BK4585","RYTM","MEDI","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662953510","title":"Rhythm Pharmaceuticals Initiated at Hold by Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662953510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662953510?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:09","pubTimestamp":1787922540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4552","BK4588","BK4566","RYTM","BK4585","MEDI","BK4118","DB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062924","title":"Rhythm Pharmaceuticals, Inc. : Deutsche Bank Initiates Coverage with Hold Rating and Target Price $120","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662062924?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:09","pubTimestamp":1787915342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nAQN2MGYV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","RYTM","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662050774","title":"Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662050774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662050774?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:35","pubTimestamp":1787906119,"startTime":"0","endTime":"0","summary":"Deutsche Bank analyst David Hoang initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Hold rating and $120 price target Rhythm is a leader i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-a-hold-at-deutsche-bank-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-initiated-with-a-hold-at-deutsche-bank-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","BK4139","BK4588","RYTM","DB","BK4118","BK4552","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662489796","title":"Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2662489796","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662489796?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:34","pubTimestamp":1787729675,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) stock is in focus after Japan’s Ministry of Health, Labour and Welfare granted marketing authorization for IMCIVREE to treat acquired hypothalamic obesity, the first approved therapy for this rare condition in Japan.\nThe Rhythm Pharmaceuticals share price has gained 11.0% over the past month and 24.0% over the past 90 days, while the 1-year total shareholder return of 12.0% sits alongside a very large 3-year total shareholder return that is more than 4x. Recent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-could-be-15-undervalued-as-japan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","RYTM","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736083","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662736083?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:50","pubTimestamp":1787655028,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-rhythm-pharmaceuticals-rytm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","GLUE","BK4581","RYTM","BK4588","MEDI","BK4539","XBI","BK4139","BK4137","XLV","LU0128526141.USD","HCSG","LU0029874061.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661763262","title":"Rhythm Pharma Says Japan Regulator Approves Imcivree for Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2661763262","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661763262?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:02","pubTimestamp":1787572925,"startTime":"0","endTime":"0","summary":"Rhythm Pharma says Japan regulator approves IMCIVREE for acquired hypothalamic obesityRhythm Pharmaceuticals won Japan MHLW marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL7f4wfK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","SG9999014039.USD","LU2210150020.SGD","BK4588","NDAQ","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","MEDI","BCDF","BK4139","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661768652","title":"Rhythm Pharmaceuticals, - Imcivree Launch in Japan Expected by End of 2026 Pending Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661768652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661768652?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8J7VHH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","BK4585","BK4588","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219899","title":"How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219899","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219899?lang=en_us&edition=fundamental","pubTime":"2026-08-22 17:21","pubTimestamp":1787390490,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children 4 years and older, and granted orphan drug designation based on positive Phase 2 and Phase 3 TRANSCEND data.\nThis regulatory shift materially broadens IMCIVREE’s addressable patient population in the UK’s rare obesity segment and underscores its clinically...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","BK4139","AIPO","VTHR","ARTY","RYTM","MEDI","BK4585","AGIX","BK4588","ISBC","BK4211","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660497555","title":"Rhythm Pharma Files Form 3 for Chief Medical Officer Manher Joshi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660497555","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660497555?lang=en_us&edition=fundamental","pubTime":"2026-08-19 05:17","pubTimestamp":1787087878,"startTime":"0","endTime":"0","summary":"Rhythm Pharma files Form 3 for Chief Medical Officer Manher JoshiRhythm Pharmaceuticals filed an initial Form 3 for Chief Medical Officer Manher Joshi, dated Aug. 17.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL1FFFGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","RYTM","BK4585","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482797","title":"Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482797","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482797?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:02","pubTimestamp":1786968168,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals appoints Manher “AJ” Joshi as chief medical officerRhythm Pharmaceuticals named Manher “AJ” Joshi as chief medical officer, effective Aug. 17.Joshi most recently served as chief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL442WgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2324357040.USD","IE00B3QW5Z07.USD","LU0109394709.USD","LU0154245756.USD","BCDF","SG9999014021.USD","BK4588","LU2065169927.USD","LU2065171311.SGD","NBIX","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU0154245673.USD","RYTM","MEDI","BK4585","ATRA","LU0314104364.USD","LU0889565916.HKD","LU2065170008.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2065171402.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU0823416689.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU0320765992.SGD","BK4139","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660822354","title":"Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660822354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660822354?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA7SVY7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","RYTM","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659577122","title":"Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659577122","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659577122?lang=en_us&edition=fundamental","pubTime":"2026-08-15 07:02","pubTimestamp":1786748565,"startTime":"0","endTime":"0","summary":"Rhythm Pharma EVP, Head of International Yann Mazabraud sells USD 6.61 million in common sharesRhythm Pharmaceuticals EVP, Head of International Yann Mazabraud cut his stake to 55,655 shares in transactions dated Aug. 12.Disposed of 56,?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3ZSG63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","MEDI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658315990","title":"UK MHRA Expands Rhythm’s Imcivree Authorization to Treat Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2658315990","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658315990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449829,"startTime":"0","endTime":"0","summary":"UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesityUK MHRA expanded IMCIVREE (setmelanotide) authorization for acquired hypothalamic obesity in patients aged 4 and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL5z8LQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B3QW5Z07.USD","BCDF","SG9999014021.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","RYTM","MEDI","BK4585","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658861990","title":"Rhythm Pharmaceuticals: to Work Closely with UK's Nhs to Finalize Guidance for Coverage of Imcivree for Acquired Ho","url":"https://stock-news.laohu8.com/highlight/detail?id=2658861990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658861990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480NY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RYTM","MEDI","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658084997","title":"Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658084997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658084997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","MEDI","BK4585","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640758","title":"Rhythm Pharmaceuticals Price Target Raised to $146.00/Share from $145.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640758?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:53","pubTimestamp":1786121580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","MEDI","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668501","title":"How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668501?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:37","pubTimestamp":1786045066,"startTime":"0","endTime":"0","summary":"In August 2026, Rhythm Pharmaceuticals reported second-quarter 2026 results showing revenue of US$71.26 million versus US$48.50 million a year earlier, alongside a net loss of US$49.30 million and slightly improved loss per share. \nThe company also released early Phase 2 data for its weekly MC4R agonist RM-718 in acquired hypothalamic obesity, showing double-digit BMI reductions with fewer pigmentation issues, highlighting progress beyond its first-generation IMCIVREE franchise. \nNow we’ll...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-q2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-q2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","RYTM","BK4211","RM","MEDI","BK4588","BK4166","BK4139","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657352510","title":"Rhythm Pharmaceuticals is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657352510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657352510?lang=en_us&edition=fundamental","pubTime":"2026-08-05 23:21","pubTimestamp":1785943260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4588","BK4585","MEDI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0413},{"period":"1month","weight":-0.072},{"period":"3month","weight":0.1891},{"period":"6month","weight":0.0986},{"period":"1year","weight":-0.0175},{"period":"ytd","weight":-0.0402}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.238637},{"month":8,"riseRate":0.777778,"avgChangeRate":0.220515},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.03963},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction